Clinical Insights: November 19, 2026
Welcome to Pillr Health’s Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace.
New Drug/Vaccine Approval
Pimjetmi® (pimicotinib) Capsules – New Drug Approval – November 10, 2026 – The Food and Drug Administration approved pimicotinib (Pimjetmi®, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. <Read More>
Sunharbo® (asundexian) Tablets – New Drug Approval – November 9, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). <Read More>
Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Injection – New Drug Approval – October 30, 2026 – The U.S. Food and Drug Administration granted accelerated approval for Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) that leads to the formation of small, wart-like growths in the patient’s airways. <Read More>
Hibsago® (bepirovirsen) Injection – New Drug Approval – October 20, 2026 – The U.S. Food and Drug Administration approved Hibsago® (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago® is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. <Read More>
Brytly™ (apraclonidine hydrochloride) Ophthalmic Solution – New Drug Approval – October 16, 2026 – The U.S. Food and Drug Administration approved a new nonprescription eye drop treatment, Brytly™, apraclonidine ophthalmic solution, 0.125%, for relief of eye redness due to minor irritations. This is the first nonprescription eye drop with apraclonidine. <Read More>
Hovilpri® (pritelivir) Tablets – New Drug Approval – October 9, 2026 – FDA has approved Hovilpri® (pritelivir) tablets for adults with weakened immune systems (i.e., immunocompromised patients) who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Mucocutaneous lesions occur on skin or mucosal surfaces, such as lips, nostrils, eyes and genitals. <Read More>
Weltruza™ (olanzapine) Powder for Extended-Release Injectable Suspension – New Drug Approval – October 8, 2026 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved Weltruza™ (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. Weltruza™ clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP). <Read More>
Emcitate® (tiratricol) Tablets for Oral Suspension – New Drug Approval – September 28, 2026 – The U.S. Food and Drug Administration approved Emcitate® (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. <Read More>
Juvmo™ (tavapadon) Tablets – New Drug Approval – September 25, 2026 - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved Juvmo™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive neurological disorder that affects millions of people worldwide. <Read More>
New Label Expansions
Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) Injection – New Expanded Label – November 5, 2026 - Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody. <Read More>
Ilumya® (tildrakizumab-asmn) Injection – New Expanded Label – October 30, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associated companies) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Ilumya® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). <Read More>
Talzenna® (talazoparib) Capsules – New Expanded Label – October 26, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna® (talazoparib) in combination with Xtandi® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. <Read More>
Skyrizi® (risankizumab-rzaa) Injection – New Expanded Label – October 23, 2026 - AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi® (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD). Patients now have the option to start Skyrizi® treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment. <Read More>
Awiqli® (insulin icodec-abae) Injection – New Expanded Label – October 23, 2026 - Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first once-weekly, long-acting basal insulin, as an adjunct to diet and exercise to improve glycemic control (blood sugar) in children 10 years of age and older with type 2 diabetes. This approval offers a once-weekly basal insulin treatment option, which reduces the frequency of weekly basal injections from seven to one per week. <Read More>
Ultomiris® (ravulizumab-cwvz) Injection – New Expanded Label – October 21, 2026 - Alexion, AstraZeneca Rare Disease’s Ultomiris® (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether Ultomiris® slows kidney function decline in patients with IgAN. <Read More>
Jemperli® (dostarlimab-gxly) Injection – New Expanded Label – October 19, 2026 - GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Jemperli® (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway. <Read More>
Orladeyo® (berotralstat) Capsules and Oral Pellets – New Expanded Label – October 16, 2026 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for use of the oral pellet formulation of once-daily Orladeyo® (berotralstat) for prophylactic therapy in adults and adolescents aged 12 years and older. The new 150 mg Orladeyo® pellet formulation provides an alternative administration option for adults and adolescents who may have difficulty swallowing, prefer not to take a capsule or choose to remain on a pellet formulation beyond age 12. <Read More>
Ryzumvi® (phentolamine mesylate) Ophthalmic Solution – New Expanded Label – October 16, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. Ryzumvi® is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. <Read More>
Enspryng® (satralizumab-mwge) Injection – New Expanded Label – October 15, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. <Read More>
Zilbrysq® (zilucoplan) Injection – New Expanded Label – October 15, 2026 - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with Zilbrysq® (zilucoplan). The autoinjector is designed to help simplify self-administration of Zilbrysq®, offering patients another administration option and a more convenient treatment experience. <Read More>
Evoxac® (cevimeline hydrochloride) Capsules and Oral Solution – New Expanded Label – October 15, 2026 - Cosette Pharmaceuticals, Inc. (“Cosette”), a U.S.-based specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Evoxac® (cevimeline HCl) oral solution for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. <Read More>
Anktiva® (nogapendekin alfa inbakicept-pmln) – New Expanded Label – October 14, 2026 - The U.S. Food and Drug Administration expanded the approved use of Anktiva® (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment. Anktiva® is the first FDA-approved treatment specifically for patients with BCG-unresponsive, high-grade papillary-only disease. <Read More>
Tecentriq® (atezolizumab) Injection – New Expanded Label – October 8, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. <Read More>
Tukysa® (tucatinib) Tablets – New Expanded Label – October 7, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Tukysa® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. <Read More>
Rhapsido® (remibrutinib) Tablets – New Expanded Label – October 6, 2026 - Novartis announced that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. The approval represents an important advancement for people whose chronic hives and itch can be triggered by everyday skin friction, scratching, or rubbing. <Read More>
Jaypirca® (pirtobrutinib) Tablets – New Expanded Label – October 2, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts the December 2023 accelerated approval for later-line CLL/SLL to a traditional approval. <Read More>
Camzyos® (mavacamten) Capsules – New Expanded Label – September 30, 2026 - Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved Camzyos® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. Camzyos® now has the broadest indication of any cardiac myosin inhibitor (CMI). <Read More>
Gazyva® (obinutuzumab) – New Expanded Label – September 25, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has received U.S. Food and Drug Administration (FDA) approval of Gazyva® (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. <Read More>
Olumiant® (baricitinib) Tablets – New Expanded Label – September 25, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Olumiant® (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA). The approval expands Olumiant®’s U.S. label, building on its established use in adults with moderately to severely active rheumatoid arthritis and severe AA. AA is a chronic immune-mediated disease that causes unpredictable hair loss. <Read More>
Yusimry® (adalimumab-aqvh) Injection – New Expanded Label – September 25, 2026 - Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced that the U.S. Food and Drug Administration (“FDA”) has approved a high-concentration formulation (“HCF”) for Yusimry® (adalimumab-aqvh), as an interchangeable biosimilar to Humira. <Read More>
New Drug Shortage
November 16, 2026
Abacavir Sulfate Injection (Discontinuation)
Lamivudine Injection (Discontinuation)
Olipudase alfa-rpcp Injection (Currently in Shortage)
November 13, 2026
Bendamustine Hydrochloride Injection (Discontinuation)
Propranolol Hydrochloride Capsule, Extended Release (Discontinuation)
Somatropin Injection (Discontinuation)
Valrubicin Solution (Discontinuation)
November 6, 2026
Lincomycin Hydrochloride Injection (Discontinuation)
November 5, 2026
Tadalafil Tablet (Discontinuation)
October 30, 2026
Cefazolin in Dextrose Injection (Discontinuation)
Cefepime Hydrochloride Injection (Discontinuation)
Ceftriaxone Sodium Injection (Discontinuation)
Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension/Drops (Discontinuation)
Updated Drug Shortage
November 13, 2026
Hydroxocobalamin Injection (Currently in Shortage)
November 10, 2026
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
November 9, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Etomidate Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Pentostatin Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
Sufentanil Citrate Injection (Currently in Shortage)
November 6, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Dexmedetomidine Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
November 4, 2026
Clonazepam Tablet (Resolved)
New Drug Recall and Safety Alerts
Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter – November 9, 2026 - Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the presence of particulate matter identified as a glass particle inside the vial. <Read More>
Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter – October 14, 2026 - Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel, that was detected in certain lots. <Read More>
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter – October 9, 2026 - Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose. <Read More>
Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels – October 1, 2026 – Greenwich RxExternal Link Disclaimer, a 503A compounding pharmacy, is voluntarily recalling specific lots of its compounded glutathione to the consumer level. The product is being recalled due to potential elevated endotoxin levels. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection – September 21, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
New Generic/Biosimilar Approval and Launch
Lucamzi™ (ranibizumab-blrz) Injection – New Lucentis® Biosimilar Approval – October 27, 2026 – Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2027 together with its partners. <Read More>
Clinical and Pharmacy News
URGENT Notice to NCPDP Pharmacy Provider Members Using IINs (BINs) Recommendations to Address Risks with the Transition from the Six-Digit IIN (BIN) to Eight-Digit IIN (BIN) – This is a notification from the NCPDP Strategic National Implementation Process (SNIP) Committee to assist pharmacy provider stakeholders with the transition from the six-digit IIN (formerly known as BIN) to the eight-digit IIN. The compliance dates associated with several CMS final rules recently published set a more distinct timeline as to when various systems and processes should begin using the eight-digit IIN. Stakeholders are encouraged to review the information and recommendations below. Also reference other NCPDP resources to coordinate implementation timelines and mitigate transaction processing barriers. <Read More>
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin – November 16, 2026 – Modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin officially took effect November 15, 2026, introducing changes intended to reduce administrative burdens for patients, prescribers, and pharmacies while maintaining safeguards against fetal exposure to the medication. <Read More>
WHO Issues First Guidelines on Type 1 Diabetes for Adults – November 14, 2026 – More than 100 years after the discovery of insulin, many people living with type 1 diabetes still cannot access the insulin and care they need to survive. Type 1 diabetes is a lifelong condition in which the body does not produce enough insulin, making people dependent on daily insulin to survive. Marking World Diabetes Day 2026, the World Health Organization (WHO) has issued its first guidelines on the diagnosis and management of type 1 diabetes in adults, with recommendations designed to apply across all settings, including low-resource, emergency and humanitarian settings. <Read More>
AHA 2026: Pharmacists at the Center of Cardiometabolic Care – November 13, 2026 - When the American Heart Association (AHA) Scientific Sessions 2026 convened in Chicago, Illinois, from November 6 to 9, 2026, the data spanned a new class of incretin-based therapy, longer-term results for the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, blood pressure effects of an oral glucagon-like peptide-1 (GLP-1) receptor agonist, and real-world models of heart failure (HF) care. Across Pharmacy Times interviews and abstract coverage from the meeting, a common theme emerged: pharmacists are increasingly central to how new cardiometabolic therapies are titrated, monitored, and sustained. <Read More>
DOL Finalizes Pharmacy Benefit Manager Fee Disclosure Rule: What PBMs Must Disclose, and Should be Ready to Defend – November 4, 2026 – Pharmacy benefit managers (PBMs) that serve large, self-insured health plans will have to give employers a detailed account of how they are paid under a rule the U.S. Department of Labor (DOL) finalized on October 29, 2026. Employers will also have the right to audit that information. PBMs have time to prepare but should not wait. A PBM that wants to rely on the 90-day advance-notice benchmark for renewals will need its disclosures ready well before the rule applies. <Read More>
How the Biosimilars Access and Affordability Act Redefines IRA Delays – November 3, 2026 - Congress is again weighing changes to how the Inflation Reduction Act (IRA) treats biologics facing imminent biosimilar competition. The Biosimilars Access and Affordability Act (H.R. 10628/S. 5571), reintroduced in both the House and Senate, would create clearer criteria for delaying Medicare price negotiation of a reference biologic when a biosimilar is expected to reach the market while keeping the IRA’s 2-year maximum delay. Under the bill, manufacturers would certify their expected launch information, and if the biosimilar is not licensed and marketed within the 2-year period, the reference biologic would enter negotiation, and its manufacturer would owe rebates covering the delayed years. <Read More>
340B in the News
Protecting the 340B Program Means Protecting Patients First – November 13, 2026 – Every month roughly 30 patients at Third Street Health Center in Ohio pick up their prescriptions for about $6. Beginning in January, some of those same prescriptions could cost them more than $500. That is what a new federal rebate pilot program means for community health centers, the providers that use the 340B Drug Pricing Program exactly as Congress intended. Plenty has been written about the abuse of 340B, but CHCs are model stewards of the program and are required to reinvest any savings back into patient care. <Read More>
340B Cuts Softened, Site-Neutral Expansion Progresses in CMS CY 2027 OPPS Final Rule – November 5, 2026 - CMS finalized 340B drug reimbursement at ASP minus 28%, less than the proposed 33.4% cut, while accelerating the annual recoupment offset to 2% through 2031. The agency will reimburse imaging without contrast at grandfathered off-campus hospital outpatient departments at the Physician Fee Schedule equivalent, setting the rate at 40% of the standard OPPS rate. Hospitals will receive a net 2.3% payment update that industry advocates criticize as insufficient, alongside the removal of 637 services from the Inpatient Only list. <Read More>
Medicare Will Cut Billions From 340B, Expand Site-Neutral Payments in 2027 – November 5, 2026 - Medicare will slash payment rates for a federal drug discount program and broaden site-neutral policies next year, according to a final rule released by the CMS on Wednesday. 340B payments are set to drop by billions of dollars and Medicare will pay the same amount for more medical procedures, regardless if they’re furnished in hospital-owned outpatient departments. Under the final rule, hospital outpatient departments and ASCs will also see their Medicare payments increase 2.3% next year, slightly less than the 2.4% bump regulators proposed in July. <Read More>
Pharmacy Benefit Managers Take Savings Intended for 340B Providers Serving Vulnerable Patients – November 4, 2026 – A “pharmacy benefit manager” is a kind of middleman company that administers prescription drug benefits for insurers and employers, managing formularies, negotiating manufacturer rebates, processing claims, and overseeing pharmacy networks…But here’s how PBMs can legally steal every day from 340B safety-net nonprofit providers that Congress intended to invest back in services for vulnerable populations. Through corporate vertical integration, PBMs such as CVS Health, Express Scripts, and OptumRx own or control pharmacies participating in 340B, allowing them to capture portions of the drug-discount margin. Five major PBMs control 75% of 340B contract-pharmacy relationships, while more than half of contract-pharmacy 340B savings are going to CVS, which owns Aetna; Cigna, which owns Express Scripts; and United Healthcare, which owns Optum Rx. <Read More>
CMS Finalizes Increases to Medicare Hospital Outpatient Department Payment Rates, Changes to Site-Neutral and 340B for 2027 – November 4, 2026 – The Centers for Medicare & Medicaid Services Nov. 4 issued a final rule that increases Medicare hospital outpatient prospective payment system rates by a net 2.3% in calendar year 2027 compared to 2026. This includes a 3.2% market basket update, offset by a 0.9 percentage point cut for productivity. In a statement shared with the media, Ashley Thompson, AHA senior vice president of public policy analysis and development, said, “CMS’ Medicare outpatient hospital payment rate does not adequately take into account the financial challenges facing hospitals today. These challenges are amplified for hospitals serving rural and underserved communities, many of which are already making hard decisions about how they will maintain access to healthcare services in their communities.” <Read More>
Understanding the Origins of the 340B Drug Pricing Program – October 29, 2026 – Although nearly half of all U.S. hospitals participate in it, few Americans have heard of the 340B Drug Pricing Program. The program was designed to allow health care providers that serve low-income and uninsured patients, such as federally qualified health centers (FQHCs), to buy drugs from manufacturers at significant discounts to offset losses from uncompensated care. However, the program has grown significantly over time to include more than 60,000 clinical sites and accounts for more than $100 billion in discounted spending. Because discounted drugs can be used for all patients — not just those who cannot pay — providers participating in the program can generate revenue from billing discounted drugs to payers, including Medicaid, Medicare, and private insurance. Critics of the program have raised questions regarding hospitals’ use of revenue from the program. <Read More>
